Medical geneticist at the University hospital of Montpellier
Key takeaways
Customised healthcare, also called “personalised medicine”, has already become a part of medical practice.
Compared to generalised treatment, medication targeting specific cancer mutations has improved patient survival; as much as 40% in the case of the BRCA1 gene.
In the future, doctors could use genomic data to evaluate a patient’s risk of developing certain diseases.
Currently, around a hundred mutated genes can lead a doctor to suggest a new treatment or preventive measures.
According to Pascal Pujol, more digital tools are needed to aid decisions around therapeutic options for patients using their genetic data.
Oncology was the first medical field to start using personalised medicine.
Whilst spectacular results have shown increased survival rates for cancer patients, there are certain limits to these techniques such as development of tumour resistance to treatments.
Now, 20 years on, this innovative approach has delivered on its promises, but it has also raised new issues that biomedical research is yet to resolve.
Inria engineer in biomechanics, Jeunes Talents France 2020 prize "For women in science" (L'Oréal-Unesco)
Key takeaways
To improve treatments, engineers are seeking ways to adapt medical interventions to suit the specific biomechanics of each patient.
In order to avoid invasive testing, the MΞDISIM team develops ways to generate digital models of patients’ organs.
Cécile Patte is working on a tool to create digital avatars of the lungs of patients suffering from pulmonary fibrosis – a chronic lung disease and one of the long-term effects of Covid-19.
These digital replicas will enable doctors to evaluate personalised treatments non-invasively.
Lecturer in economic science at the University of Bourgogne
Key takeaways
Personalised medicine produces a lot of data, some of which is not directly connected to the original intended analysis and can even include data relating to the patient’s family.
This raises questions on how to communicate this information and its value for the doctor, the patient, and society at large.
It is also very difficult to accurately assess all the cost vs. benefits of personalised healthcare.
Lastly, this new health model involves ethical considerations, to ensure that access to these new treatments is equitable.
Director of Research in Statistics at Inria and Professor at the Centre for Applied Mathematics (CMAP*) at the École Polytechnique (IP Paris)
Jonathan Chauvin
CEO at Lixoft
Key takeaways
Personalised medicine produces a lot of data, some of which is not directly connected to the original intended analysis and can even include data relating to the patient’s family.
This raises questions on how to communicate this information and its value for the doctor, the patient, and society at large.
It is also very difficult to accurately assess all the cost vs. benefits of personalised healthcare.
Lastly, this new health model involves ethical considerations, to ensure that access to these new treatments is equitable.
Contributors
Agnès Vernet
Science journalist
After her initial studies in molecular biology, Agnès Vernet trained as a science journalist at ESJ-Lille. For the past 14 years, she has been writing for various media, scientific magazines, professional titles and general press, in France and Switzerland. Since 1st February 2021, she is the elected President of the French association of science journalists (AJSPI).